Lyden D, Welch DR, Psaila B. Cancer metastasis: biologic basis and therapeutics. Cambridge University Press; 2011.
Gerratana L, Fanotto V, Bonotto M, Bolzonello S, Minisini AM, Fasola G, et al. Pattern of metastasis and outcome in patients with breast cancer. Clinical & Experimental Metastasis. 2015;32:125–33.
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537–49.
Feys L, Descamps B, Vanhove C, Vral A, Veldeman L, Vermeulen S, et al. Radiation-induced lung damage promotes breast cancer lung-metastasis through CXCR4 signaling. Oncotarget. 2015;6:26615–32.
Mansel WG, R. E., Fodstad, O. & Jiang. Metastasis of breast cancer. Netherland: Springer; 2007.
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. Journal of Clinical Oncology : official Journal of the American Society of Clinical Oncology. 2010;28:3271–7.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO. 2011;22:1736–47.
Karlsson E, Appelgren J, Solterbeck A, Bergenheim M, Alvariza V, Bergh J. Breast cancer during follow-up and progression—a population based cohort on new cancers and changed biology. European Journal of Cancer. 2014;50:2916–24.
Mendes D, Alves C, Afonso N, Cardoso F, Passos-Coelho JL, Costa L, et al. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer–a systematic review. Breast Cancer Research. 2015;17:1–14.
Bhoo-Pathy N, Verkooijen HM, Tan EY, Miao H, Taib NA, Brand JS, et al. Trends in presentation, management and survival of patients with de novo metastatic breast cancer in a Southeast Asian setting. Scientific Reports. 2015;5:16252.
Weigelt B, Peterse JL, LJVt V. Breast cancer metastasis: markers and models. Nature Reviews Cancer. 2005;5:591–602.
Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 2006;12:6403–9.
Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. Journal of Mammary Gland Biology and Neoplasia. 2002;7:3–15.
Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: new perspectives. Annual Review of Medicine. 2010;61:301–16.
Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism. 2014;86:16–23.
Arpino G, Milano M, Placido SD. Features of aggressive breast cancer. The Breast. 2015;5:594–600.
Demoor-Goldschmidt C, Fayech C, Girard P, Plantaz D. Secondary cancers: Incidence, risk factors and recommendations. Bulletin du Cancer. 2015;102:656–64.
Duchnowska R, Dziadziuszko R, Czartoryska-Arłukowicz B, Radecka B, Szostakiewicz B, Sosińska-Mielcarek K, et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Research and Treatment. 2009;117:297–303.
Yalcin B. Staging, risk assessment and screening of breast cancer. Experimental Oncology. 2013:238–45.
Park NJ, Kang DH. Inflammatory cytokine levels and breast cancer risk factors: racial differences of healthy Caucasian and African American women. Oncology Nursing Forum. 2013;40:490–500.
Zaritsky E, Dibble SL. Risk factors for reproductive and breast cancers among older lesbians. Journal of Women's Health. 2010;19:125–31.
Jokiel M, Bielska-Lasota M. Breast cancer risk factors–possibilities of primary prevention. Przeglad Epidemiologiczny. 2010;64:435–8.
Torres D, Myers JA, Eshraghi LW, Riley EC, Soliman PT, Milam MR. Risk factors for the development of uterine cancer in breast cancer survivors: an army of women study. Annals of Surgical Oncology. 2015;22:1974–9.
Ambroggi M, Stroppa EM, Mordenti P, Biasini C, Zangrandi A, Michieletti E, et al. Metastatic breast cancer to the gastrointestinal tract: report of five cases and review of the literature. International Journal of Breast Cancer. 2012;
Bertozzi S, Londero AP, Cedolini C, Uzzau A, Seriau L, Bernardi S, et al. Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer. SpringerPlus. 2015;4:1–8.
Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nature Reviews Drug Discovery. 2012;11:479–97.
Rivenbark AG, Coleman WB. Field cancerization in mammary carcinogenesis—Implications for prevention and treatment of breast cancer. Experimental and Molecular Pathology. 2012;93:391–8.
Fidler IJ. The pathogenesis of cancer metastasis: the'seed and soil'hypothesis revisited. Nature Reviews Cancer. 2003;3:453–8.
Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006;127:679–95.
Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nature Medicine. 2001;7:192–8.
Bernards R, Weinberg RA. Metastasis genes: a progression puzzle. Nature. 2002;418:823.
Patel LR, Camacho DF, Shiozawa Y, Pienta KJ, Taichman RS. Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncology. 2011;7:1285–97.
Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Research. 2005;65:5991–5. discussion 5
Chambers AF, Groom AC, Metastasis MDIC. dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer. 2002;2:563–72.
Coleman RE, Gregory W, Marshall H, Wilson C, Holen I. The metastatic microenvironment of breast cancer: clinical implications. The Breast. 2013;22:S50–S6.
Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13:58–68.
de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137(2):183–92. https://doi.org/10.1007/s00432-010-0957-x.
Neophytou C, Boutsikos P, Papageorgis P. Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis. Front Oncol. 2018;8:31. https://doi.org/10.3389/fonc.2018.00031.
McGee SF. Understanding metastasis: current paradigms and therapeutic challenges in breast cancer progression. RCSI Student Medical Journal. 2010;3:56–60.
Rudland PS, Platt-Higgins A, El-Tanani M, Rudland SDS, Barraclough R, Winstanley JH, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Research. 2002;62:3417–27.
Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015;112(9):1445–51. https://doi.org/10.1038/bjc.2015.127.
Mahmood H, Faheem M, Mahmood S, Sadiq M, Irfan J. Impact of age, tumor size, lymph node metastasis, stage, receptor status and menopausal status on overall survival of breast cancer patients in Pakistan. Asian Pacific journal of cancer prevention : APJCP. 2015;16:1019–24.
Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls E-B, et al. The prognostic impact of age in different molecular subtypes of breast cancer. Breast Cancer Research and Treatment. 2015;152:667–73. https://doi.org/10.1007/s10549-015-3491-3.
Ribnikar D, Ribeiro JM, Pinto D, Sousa B, Pinto AC, Gomes E, et al. Breast cancer under age 40: a different approach. Current Treatment Options in Oncology. 2015;16:16. https://doi.org/10.1007/s11864-015-0334-8.
Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, Stewart JH. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. American Journal of Surgery. 2013;205:397–401. https://doi.org/10.1016/j.amjsurg.2013.01.009.
Bailes AA, Kuerer HM, Lari SA, Jones LA, Brewster AM. Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast. Cancer. 2013;119:150–7. https://doi.org/10.1002/cncr.27707.
Weston MK, Moss DP, Stewart J, Hill AG. Differences in breast cancer biological characteristics between ethnic groups in New Zealand. Breast Cancer Research and Treatment. 2008;111:555–8. https://doi.org/10.1007/s10549-007-9813-3.
de Oliveira Filho HR, Dória MT, Piato JRM, Soares Junior JM, Filassi JR, Baracat EC, et al. Criteria for prediction of metastatic axillary lymph nodes in early-stage breast cancer. Revista Brasileira De Ginecologia E Obstetrícia: Revista Da Federação Brasileira Das Sociedades De Ginecologia E Obstetrícia. 2015;37:308–13. https://doi.org/10.1590/S0100-720320150005343.
Milner TD, de Lusignan S, Jones S, Jackson PA, Layer GT, Kissin MW, et al. Breast cancer metastasis burden in sentinel nodes analysed using one-step nucleic acid amplification predicts axillary nodal status. Breast (Edinburgh, Scotland). 2015;24:568–75. https://doi.org/10.1016/j.breast.2015.05.004.
Wen J, Ye F, Huang X, Li S, Yang L, Xiao X, et al. The tumor-to-breast volume ratio (TBR) predicts cancer-specific survival in breast cancer patients who underwent modified radical mastectomy. Tumor Biology. 2015:1–8.
Xue C, Fu F, Wang C. Analysis of prognostic parameters in patients with breast cancer of size smaller than or equal to 2 cm. Zhonghua bing li xue za zhi Chinese Journal of Pathology. 2015;44:245–9.
Ren Z, Li Y, Shen T, Hameed O, Siegal GP, Wei S. Prognostic factors in advanced breast cancer: race and receptor status are significant after development of metastasis. Pathol Res Pract. 2016;212(1):24–30. https://doi.org/10.1016/j.prp.2015.11.003.
Singh JK, Farnie G, Bundred NJ, Simões BM, Shergill A, Landberg G, et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clinical Cancer Research. 2013;19:643–56. https://doi.org/10.1158/1078-0432.CCR-12-1063.
Lianidou ES, Markou A, Strati A. The role of CTCs as tumor biomarkers. Advances in Experimental Medicine and Biology. 2015;867:341–67. https://doi.org/10.1007/978-94-017-7215-0_21.
Pantel K, Alix-Panabières C. Functional studies on viable circulating tumor cells. Clinical Chemistry. 2015; https://doi.org/10.1373/clinchem.2015.242537.
Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, et al. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast Cancer Research and Treatment. 2015;154:563–71. https://doi.org/10.1007/s10549-015-3636-4.
Hall CS, Karhade M, Laubacher BA, Kuerer HM, Krishnamurthy S, DeSnyder S, et al. Circulating tumor cells and recurrence after primary systemic therapy in stage III inflammatory breast cancer. Journal of the National Cancer Institute. 2015;107 https://doi.org/10.1093/jnci/djv250.
Kanwar N, Hu P, Bedard P, Clemons M, McCready D, Done SJ. Identification of genomic signatures in circulating tumor cells from breast cancer. International Journal of Cancer. 2015;137:332–44. https://doi.org/10.1002/ijc.29399.
McInnes LM, Jacobson N, Redfern A, Dowling A, Thompson EW, Saunders CM. Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity. Frontiers in Oncology. 2015;5:42. https://doi.org/10.3389/fonc.2015.00042.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine. 2004;351:781–91.
Beenken SW, Bland KI. Biomarkers for breast cancer. Minerva Chirurgica. 2002;57:437–48.
Ren C, Han C, Fu D, Wang D, Chen H, Chen Y, et al. Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy. Int J Cancer. 2016;138(7):1586–600. https://doi.org/10.1002/ijc.29679.
Gujam FJA, Going JJ, Mohammed ZMA, Orange C, Edwards J, McMillan DC. Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC cancer. 2014;14:676. https://doi.org/10.1186/1471-2407-14-676.
Sahoo PK, Jana D, Mandal PK, Basak S. Effect of lymphangiogenesis and lymphovascular invasion on the survival pattern of breast cancer patients. Asian Pacific Journal of Cancer Prevention: APJCP. 2014;15:6287–93.
Rakha EA, Martin S, Lee AHS, Morgan D, Pharoah PDP, Hodi Z, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118:3670–80. https://doi.org/10.1002/cncr.26711.
Kuroda H, Nakai M, Ohnisi K, Ishida T, Kuroda M, Itoyama S. Vascular invasion in triple-negative carcinoma of the breast identified by endothelial lymphatic and blood vessel markers. International Journal of Surgical Pathology. 2010;18:324–9. https://doi.org/10.1177/1066896910375563.
Ragage F, Debled M, MacGrogan G, Brouste V, Desrousseaux M, Soubeyran I, et al. Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer? Cancer. 2010;116:3093–101. https://doi.org/10.1002/cncr.25137.
Van den Eynden GG, Van der Auwera I, Van Laere SJ, Colpaert CG, van Dam P, Dirix LY, et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. British Journal of Cancer. 2006;94:1643–9. https://doi.org/10.1038/sj.bjc.6603152.
Dian D, Heublein S, Wiest I, Barthell L, Friese K, Jeschke U. Significance of the tumor protease cathepsin D for the biology of breast cancer. Histology and Histopathology. 2014;29:433–8.
Dian D, Vrekoussis T, Shabani N, Mylonas I, Kuhn C, Schindlbeck C, et al. Expression of cathepsin-D in primary breast cancer and corresponding local recurrence or metastasis: an immunohistochemical study. Anticancer Research. 2012;32:901–5.
Han Z, Chen Z, Zheng R, Cheng Z, Gong X, Wang D. Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis. World Journal of Surgical Oncology. 2015;13:56. https://doi.org/10.1186/s12957-015-0486-9.
Rykala J, Przybylowska K, Majsterek I, Pasz-Walczak G, Sygut A, Dziki A, et al. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathology Oncology Research: POR. 2011;17:809–17. https://doi.org/10.1007/s12253-011-9387-6.
Boneberg E-M, Legler DF, Hoefer MM, Ohlschlegel C, Steininger H, Füzesi L, et al. Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. British Journal of Cancer. 2009;101:605–14. https://doi.org/10.1038/sj.bjc.6605219.
Liu Y, Ma L, Liu X, Wang L. Expression of human mammaglobin as a marker of bone marrow micrometastasis in breast cancer. Experimental and Therapeutic Medicine. 2012;3:550–4. https://doi.org/10.3892/etm.2011.429.
Duffy MJ, McGowan PM, Harbeck N, Thomssen C, uPA SM. PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Research : BCR. 2014;16 https://doi.org/10.1186/s13058-014-0428-4.
Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, et al. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. International Journal of Oncology. 2006;28:807–14.
Grawenda AM, Møller EK, Lam S, Repapi E, Teunisse AFAS, Alnæs GIG, et al. Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer. Cancer Research. 2015;75:698–708. https://doi.org/10.1158/0008-5472.CAN-14-2637.
Di Minin G, Bellazzo A, Dal Ferro M, Chiaruttini G, Nuzzo S, Bicciato S, et al. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Molecular Cell. 2014;56:617–29. https://doi.org/10.1016/j.molcel.2014.10.013.
Loskutova KS, Kirillina MP, Lushnikova EL, Nepomnyashchikh LM. Immunohistochemical study of apoptotic marker p53 as a prognostic factor in breast cancer. Bulletin of Experimental Biology and Medicine. 2014;158:84–7. https://doi.org/10.1007/s10517-014-2698-3.
Ermiah E, Buhmeida A, Abdalla F, Khaled BR, Salem N, Pyrhönen S, et al. Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in libya. Journal of Cancer. 2012;3:421–31. https://doi.org/10.7150/jca.4944.
Moureau-Zabotto L, Bouchet C, Cesari D, Uzan S, Lefranc J-P, Antoine M, et al. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer. Breast Cancer Research and Treatment. 2005;91:61–71. https://doi.org/10.1007/s10549-004-7047-1.
Midulla C, Cenci M, De Iorio P, Pisani T, Bonaccorsi A, De Marchis L, et al. DNA ploidy and TLI in association with other prognostic parameters in breast cancer. Anticancer Research. 1999;19:381–4.
Meyer JS, Hixon B. Advanced stage and early relapse of breast carcinomas associated with high thymidine labeling indices. Cancer Research. 1979;39:4042–7.
Shokouh TZ, Ezatollah A, Barand P. Interrelationships between Ki67, HER2/neu, p53, ER, and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes: retrospective-observational analytical study. Medicine. 2015;94:e1359. https://doi.org/10.1097/MD.0000000000001359.
Falato C, Lorent J, Tani E, Karlsson E, Wright PK, Bergh J, et al. Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer. Breast Cancer Research and Treatment. 2014;147:407–14. https://doi.org/10.1007/s10549-014-3096-2.
Yin Y, Zeng K, Wu M, Ding Y, Zhao M, Chen Q. The levels of Ki-67 positive are positively associated with lymph node metastasis in invasive ductal breast cancer. Cell Biochemistry and Biophysics. 2014;70:1145–51. https://doi.org/10.1007/s12013-014-0034-1.
Takashima T, Onoda N, Ishikawa T, Ogawa Y, Kato Y, Fujimoto Y, et al. Proliferating cell nuclear antigen labeling index and p53 expression predict outcome for breast cancer patients with four or more lymph node metastases. International Journal of Molecular Medicine. 2001;8:159–63.
Thomassen M, Tan Q, Eiriksdottir F, Bak M, Cold S, Kruse TA. Comparison of gene sets for expression profiling: prediction of metastasis from low-malignant breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2007;13:5355–60. https://doi.org/10.1158/1078-0432.CCR-07-0249.
Matouskova E, Kudlackova I, Chaloupkova A, Brozova M, Netikova I, Vesely P. Origin of cells cultured in vitro from human breast carcinomas traced by cyclin D1 and HER2/neu FISH signal numbers. Anticancer Research. 2005;25:1051–7.
Durbecq V, Di Leo A, Cardoso F, Rouas G, Leroy JY, Piccart M, et al. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Research and Treatment. 2003;77:199–204.
Vaage J. Metastasizing potentials of mouse mammary tumors and their metastases. International Journal of Cancer. 1988;41:855–8.
Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004;23:7274–82. https://doi.org/10.1038/sj.onc.1207947.
Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science. 1977;197:893–5. https://doi.org/10.1126/science.887927.
Rs K, C W, B K, A L, Ml B. Clonal dominance of primary tumours by metastatic cells: genetic analysis and biological implications. Cancer Surveys. 1987;7:597–629.
van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6. https://doi.org/10.1038/415530a.
Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, et al. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. Journal of Clinical Investigation. 2005;115:44–55. https://doi.org/10.1172/JCI200522320.
Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJF, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proceedings of the National Academy of Sciences. 2003;100:7737–42. https://doi.org/10.1073/pnas.1331931100.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences. 2003;100:3983–8. https://doi.org/10.1073/pnas.0530291100.
Bissell MJ, LaBarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell. 2005;7:17–23. https://doi.org/10.1016/j.ccr.2004.12.013.
Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332–7. https://doi.org/10.1038/nature03096.
Stein S, DeMichele A, Domchek S, Fox K. Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu. Clinical Breast Cancer. 2004;4:S117–S20.
O’Shaughnessy J, McIntyre K, Schwartzberg L, Wilks S, Puhalla S, Berrak E, et al. Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies. SpringerPlus. 2015;4:1–10.
Matter M, Dusmet M, Chevalley F. The place of surgery in the treatment of advanced localized, recurrent and metastatic breast cancer. Revue Medicale de la Suisse Romande. 2000;120:485–90.
Matsunaga S, Shuto T, Kawahara N, Suenaga J, Inomori S, Fujino H. Gamma Knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype: Clinical article. Journal of Neurosurgery. 2010;113:65–72.
Szychta P, Zadrozny M, Lewinski A, Karbownik-Lewinska M. Increased oxidative damage to membrane lipids following surgery for breast cancer. Neuroendocrinology Letters. 2014;35:602–7.
Yu L, Yang Y, Hou J, Zhai C, Song Y, Zhang Z, et al. MicroRNA-144 affects radiotherapy sensitivity by promoting proliferation, migration and invasion of breast cancer cells. Oncology Reports. 2015;34:1845–52.
Murphy CT, Li T, Wang LS, Obeid EI, Bleicher RJ, Eastwick G, et al. Comparison of adjuvant radiation therapy alone versus radiation therapy and endocrine therapy in elderly women with early-stage, hormone receptor-positive breast cancer treated with breast-conserving surgery. Clin Breast Cancer. 2015;15(5):381–9. https://doi.org/10.1016/j.clbc.2015.02.005.
Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, et al. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. European Journal of Cancer. 2012;48:1932–8.
Shioi Y, Kashiwaba M, Inaba T, Komatsu H, Sugai T, Wakabayashi G. Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor. The American Journal of Case Reports. 2014;15:85.
Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ. Breast cancer: current and future endocrine therapies. Molecular and Cellular Endocrinology. 2014;382:695–723.
McBryan J, Theissen SM, Byrne C, Hughes E, Cocchiglia S, Sande S, et al. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Research. 2012;72:548–59.
Jurado JC, Aznar PR, Mata JG, Martínez RF, Fernández IP, Gimeno TS, et al. Management of patients with metastatic breast cancer. Advances in Therapy. 2011;28:50–65.
Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2014;32:3948–58.
Wells SA, Santen RJ. Ablative procedures in patients with metastatic breast carcinoma. Cancer. 1984;53:762–5.
Tanaka K, Tokunaga E, Yamashita N, Taketani K, Akiyoshi S, Morita M, et al. A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer. Surgery Today. 2014;44:1678–84.
Lintermans A, Asten KV, Wildiers H, Laenen A, Paridaens R, Weltens C, et al. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Research and Treatment. 2014;146:109–16.
Chavarri-Guerra Y, Higgins MJ, Szymonifka J, Cigler T, Liedke P, Partridge A, et al. Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy. British Journal of Cancer. 2014;111:2046–50.
Ko KL, Shin IS, You JY, Jung S-Y, Ro J, Lee ES. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients. Breast Cancer Research and Treatment. 2013;142:559–67.
Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwartz NS, et al. ERRalpha is a marker of tamoxifen response and survival in triple-negative breast cancer. Clin Cancer Res. 2016;22(6):1421–31. https://doi.org/10.1158/1078-0432.CCR-15-0857.
Ishizuna K, Ninomiya J, Ogawa T, Tsuji E, Kojima M, Kawashima M, et al. Efficacy of high-dose toremifene therapy in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors:a retrospective, single-institution study. Gan to Kagaku RyohoCancer & Chemotherapy. 2014;41:965–70.
Araki K, Ishida N, Horii R, Takahashi S, Akiyama F, Ito Y, et al. Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure. Expert Opinion on Pharmacotherapy. 2015:1–8.
Boni C, Pagano M, Panebianco M, Bologna A, Sierra NM, Gnoni R, et al. Therapeutic activity of testoterone in metastatic breast cancer. Anticancer Research. 2014;34:1287–90.
Grattarola R, Secreto G, Recchione C. Androgens in breast cancer. III. Breast cancer recurrences years after mastectomy and increased androgenic activity. American Journal of Obstetrics and Gynecology. 1975;121:169–72.
Iwase H, Yamamoto Y, Yamamoto-Ibusuki M, Murakami KI, Okumura Y, Tomita S, et al. Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study. British Journal of Cancer. 2013;109:1537–42.
Xiangying M, Shikai W, Zefei J, Bing S, Yan M, Xin Z, et al. Progestin as an alternative treatment option for multi-treated recurrent triple-negative breast cancer. Swiss Med Wkly. 2013;w13765:143.
Libson S, Lippman M. A review of clinical aspects of breast cancer. International Review of Psychiatry. 2014;26:4–15.
Pac JA. Current progress in the treatment of metaplastic breast carcinoma. Asian Pacific Journal of Cancer Prevention. 2013;14:6221–5.
Yun S, Vincelette ND, Abraham I. Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgraduate Medical Journal. 2015;91:627–33.
Vera T, D'Agostino RB, Jordan JH, Whitlock MC, Meléndez GC, Lamar ZS, et al. Relation of pre-anthracycline serum bilirubin levels to left ventricular ejection fraction after chemotherapy. The American Journal of Cardiology. 2015;116:1752–5.
Rhea IB, Oliveira GH. Illuminating anthracycline cardiotoxicity: the renaissance of evidence-based onco-cardiology. Journal of Thoracic Disease. 2015;7:1111.
Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 2015;75:659–70.
Bachegowda LS, Makower DF, Sparano JA. Taxanes: impact on breast cancer therapy. Anti-Cancer Drugs. 2014;25:512–21.
Park JS, Jeung H-C, Rha SY, Ahn JB, Kang B, Chon HJ, et al. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. Cancer Chemotherapy and Pharmacology. 2014;74:799–808.
Nerich V, Chelly J, Montcuquet P, Chaigneau L, Villanueva C, Fiteni F, et al. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners. 2014;20:362–8.
Crown J, Kennedy MJ, Tresca P, Marty M, Espie M, Burris HA, et al. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO. 2013;24:2005–11.
Chan D, Yeo W-L, Cordero MT, Wong C-I, Chuah B, Soo R, et al. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. Investigational New Drugs. 2010;28:859–65.
Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, et al. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO. 2010;21:961–7.
Pentheroudakis G, Razis E, Athanassiadis A, Pavlidis N, Fountzilas G. Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer. Medical Oncology. 2006;23:147–60.
Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2006;24:2786–92.
Laessig D, Stemmler HJ, Vehling-Kaiser U, Fasching PA, Melchert F, Kolbl H, et al. Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology. 2007;73:407–14.
Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitraki E, Kontopodis E, et al. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline-and taxane-pretreated patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 2012;70:169–76.
Hong JY, Park YH, Choi MK, Jung HA, Lee SJ, Ahn JS et al. Characterization of durable responder for capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Clinical Breast Cancer. 2015;5:e287–92.
Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485–93.
Dranitsaris G, Beegle N, Kalberer T, Blau S, Cox D. Faria C. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting. Journal of Oncology Pharmacy Practice : official Publication of the International Society of Oncology Pharmacy Practitioners. 2015;21:170–7.
Huang HY, Jiang ZF, Wang T, Zhang SH, Bian L, Cao Y, et al. Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer. Zhonghua zhong liu za zhi [Chinese Journal of Oncology]. 2011;33:850–3.
Okamura R, Kato T, Sata R. Oral combination chemotherapy with capecitabine and cyclophosphamide in combination with endocrine therapy and anti-HER2 therapy for advanced and metastatic breast cancer. Nihon rinshoJapanese Journal of Clinical Medicine. 2012;70(Suppl 7):592–6.
Villanueva C, Awada A, Campone M, Machiels J-P, Besse T, Magherini E, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. European Journal of Cancer. 2011;47:1037–45.
Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM, Group NCCT. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO. 2009;20:449–53.
Kontopodis E, Kentepozidis N, Christophyllakis C, Boukovinas I, Kalykaki A, Kalbakis K, et al. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 2015;75:153–60.
Amadori D, Cecconetto L. Gemcitabine and taxanes in metastatic breast cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO. 2006;17(Suppl 5):v173–6.
Eichler K, Jakobi S, Gruber-Rouh T, Hammerstingl R, Vogl TJ, Zangos S. Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer. European Journal of Radiology. 2013;82:e816–e22.
El-Mabhouh AA, Nation PN, Abele JT, Riauka T, Postema E, McEwan AJB, et al. A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 2011;19:287–95.
Erten C, Demir L, Somali I, Alacacioglu A, Kucukzeybek Y, Akyol M, et al. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases: a preferential option for triple negative patients? Asian Pacific Journal of Cancer Prevention. 2013;14:3711–7.
Kim JS, Park IH, Lee KS, Ro J. Outcomes of palliative weekly low-dose gemcitabine-cisplatin chemotherapy in anthracycline-and taxane-pretreated metastatic breast cancer patients. Journal of Breast Cancer. 2014;17:339–43.
Stemmler HJ, Freier W, Tessen HW, Gitsch G, Jonat W, Brugger W, et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer. 2011;104:1071–8.
Anton A, Lluch A, Casado A, Provencio M, Munoz M, Lao J, et al. Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer. Anticancer Research. 2010;30:2255–61.
Awada A, Dirix L, Sanchez LM, Xu B, Luu T, Dieras V, et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO. 2013;24:109–16.
Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO. 2006;17:623–9.
Aapro M, Finek J. Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. Cancer Treatment Reviews. 2012;38:120–6.
Finek J Jr, Holubec L Jr, Svoboda T, Sefrhansova L, Pavlikova I, Votavova M, et al. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Research. 2009;29:667–70.
Sasada S, Ohtani S, Kim R, Higaki K. Clinical effect of Vinorelbine monotherapy in 18 cases of advanced or metastatic breast cancer. Gan to Kagaku RyohoCancer & Chemotherapy. 2008;35:1703–7.
Tawfik H, Rostom Y, Elghazaly H. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 2013;71:913–9.
Zhang J, Gu S-Y, Gan Y, Wang Z-H, Wang B-Y, Guo H-Y, et al. Vinorelbine and capecitabine in anthracycline-and/or taxane-pretreated metastatic breast cancer: sequential or combinational? Cancer Chemotherapy and Pharmacology. 2013;71:103–13.
Fan Y, Xu B, Yuan P, Wang J, Ma F, Li Q, et al. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Chemotherapy. 2010;56:340–7.
Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. The Lancet Oncology. 2007;8:219–25.
Addeo R, Sperlongano P, Montella L, Vincenzi B, Carraturo M, Iodice P, et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemotherapy and Pharmacology. 2012;70:603–9.
Alistar A, Chou JW, Nagalla S, Black MA, D'Agostino R, Miller LD. Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Medicine. 2014;6:80. https://doi.org/10.1186/s13073-014-0080-8.
Terunuma H. Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004. Journal of Stem Cells & Regenerative Medicine. 2012;8:205–6.
Carvalho MI, Guimarães MJ, Pires I, Prada J, Silva-Carvalho R, Lopes C, et al. EGFR and microvessel density in canine malignant mammary tumours. Research in Veterinary Science. 2013;95:1094–9. https://doi.org/10.1016/j.rvsc.2013.09.003.
Castillo-Pichardo L, Dharmawardhane SF. Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Nutrition and Cancer. 2012;64:1058–69. https://doi.org/10.1080/01635581.2012.716898.
El Guerrab A, Zegrour R, Nemlin C-C, Vigier F, Cayre A, Penault-Llorca F, et al. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS ONE. 2011;6:e25080. https://doi.org/10.1371/journal.pone.0025080.
Hsieh C-Y, Tsai P-C, Tseng C-H, Yl C, Chang LS, Lin SR. Inhibition of EGF/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells. Toxicology in Vitro. 2013;27:1–10. https://doi.org/10.1016/j.tiv.2012.10.001.
Nickerson NK, Mohammad KS, Gilmore JL, Crismore E, Bruzzaniti A, Guise TA, et al. Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS ONE. 2012;7:e30255. https://doi.org/10.1371/journal.pone.0030255.
Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, et al. Treatment of triple-negative breast cancer using anti-EGFR–directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP Inhibitor. Journal of Nuclear Medicine. 2013;54:913–21. https://doi.org/10.2967/jnumed.112.111534.
Modi S, D'Andrea G, Norton L, Yao TJ, Caravelli J, Rosen PP, et al. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clinical Breast Cancer. 2006;7:270–7. https://doi.org/10.3816/CBC.2006.n.040.
Trédan O, Campone M, Jassem J, Vyzula R, Coudert B, Pacilio C, et al. Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. Clinical Breast Cancer. 2015;15:8–15. https://doi.org/10.1016/j.clbc.2014.07.007.
Nechushtan H, Vainer G, Stainberg H, Salmon AY, Hamburger T, Peretz T. A phase 1/2 of a combination of cetuximab and taxane for "triple negative" breast cancer patients. Breast (Edinburgh, Scotland). 2014;23:435–8. https://doi.org/10.1016/j.breast.2014.03.003.
Bramati A, Girelli S, Torri V, Farina G, Galfrascoli E, Piva S, et al. Efficacy of biological agents in metastatic triple-negative breast cancer. Cancer Treatment Reviews. 2014;40:605–13. https://doi.org/10.1016/j.ctrv.2014.01.003.
Somlo G, Martel CL, Lau SK, Frankel P, Ruel C, Gu L, et al. A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Research and Treatment. 2011;131:899–906. https://doi.org/10.1007/s10549-011-1850-2.
Addison CL, Pond GR, Cochrane B, Zhao H, Chia SK, Levine MN, et al. Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: an OCOG ZAMBONEY sub-study. Journal of Bone Oncology. 2015;4:47–53. https://doi.org/10.1016/j.jbo.2015.04.001.
De Luca A, D'Alessio A, Maiello MR, Gallo M, Bevilacqua S, Frezzetti D, et al. Vandetanib as a potential treatment for breast cancer. Expert Opinion on Investigational Drugs. 2014;23:1295–303. https://doi.org/10.1517/13543784.2014.942034.
Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, et al. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemotherapy and Pharmacology. 2013;71:1183–90. https://doi.org/10.1007/s00280-013-2112-2.
Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment. 2009;115:115–21. https://doi.org/10.1007/s10549-008-0055-9.
Jankowitz RC, Abraham J, Tan AR, Limentani SA, Tierno MB, Adamson LM, et al. Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemotherapy and Pharmacology. 2013;72:1205–12. https://doi.org/10.1007/s00280-013-2262-2.
Orphanos G, Kountourakis P. Targeting the HER2 receptor in metastatic breast cancer. Hematology/Oncology and Stem Cell Therapy. 2012;5:127–37. https://doi.org/10.5144/1658-3876.2012.127.
Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2–positive breast cancer. Journal of Clinical Oncology. 2014;32:3626–33. https://doi.org/10.1200/JCO.2014.56.3809.
Chow LW-C, Xu B, Gupta S, Freyman A, Zhao Y, Abbas R, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. British Journal of Cancer. 2013;108:1985–93. https://doi.org/10.1038/bjc.2013.178.
Geuna E, Montemurro F, Aglietta M, Valabrega G. Potential of afatinib in the treatment of patients with HER2-positive breast cancer. Breast Cancer : Targets and Therapy. 2012;4:131–7. https://doi.org/10.2147/BCTT.S25868.
Zhang X, Munster PN. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opinion on Pharmacotherapy. 2014;15:1277–88. https://doi.org/10.1517/14656566.2014.913570.
Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 2012;134:1149–59. https://doi.org/10.1007/s10549-012-2126-1.
Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research and Treatment. 2012;133:1057–65. https://doi.org/10.1007/s10549-012-2003-y.
Choi Y-J, Nam S-J, Son MJ, Kim D-K, Kim J-H, Yang J-H, et al. Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model. Oncology Reports. 2006;16:119–22.
Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England Journal of Medicine. 2012;366:109–19.
Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharmaceutical Research. 2011;29:770–81. https://doi.org/10.1007/s11095-011-0601-8.
Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2010;28:92–8.
Jackisch C, Schoenegg W, Reichert D, Welslau M, Selbach J, Harich H-D, et al. Trastuzumab in advanced breast cancer-a decade of experience in Germany. BMC Cancer. 2014;14:924.
Witzel I, Müller V, Abenhardt W, Kaufmann M, Schoenegg W, Schneeweis A, et al. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer-results from the HER-OS patient registry. BMC Cancer. 2014;14:806.
Negri E, Zambelli A, Franchi M, Rossi M, Bonifazi M, Corrao G, et al. Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: a controlled cohort study. The Oncologist. 2014;19:1209–15.
Sengoku N, Tanino H, Kosaka Y, Kikuchi M, Nishimiya H, Waraya M, et al. The safety of concentrated trastuzumab in 100 ml of saline solution for administration to patients with HER2-positive breast cancer: a phase 1 study. Chemotherapy. 2014;60:1–6.
Sendur MA, Aksoy S, Ozdemir NY, Yazici O, Zengin N, Altundag K. The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration. Current Medical Research & Opinion. 2014;30:2535–42.
Croom KF, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabineas first-line therapy for HER2-negative metastatic breast cancer. Drugs. 2011;71:2213–29.
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002;20:1800–8.
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of Clinical Oncology : official Journal of the American Society of Clinical Oncology. 2005;23:4265–74.
Bayo-Calero JL, Mayordomo JI, Sánchez-Rovira P, Pérez-Carrión R, Illaramendi JJ, García-Bueno JM, et al. A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. Clinical Breast Cancer. 2008;8:264–8.
Chan A, Martin M, Untch M, Gil MG, Guillem-Porta V, Wojtukiewicz M, et al. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. British Journal of Cancer. 2006;95:788–93.
Fujisawa M, Uomori T, Takehara K, Mitsugi Y, Yoshino K, Okumura M, et al. A case of recurrent breast cancer responding to vinorelbine/trastuzumab combination therapy. Gan to Kagaku RyohoCancer & Chemotherapy. 2009;36:2631–5.
Kalsi R, Feigenberg S, Kwok Y, Tkaczuk K, Mehta M, Chumsri S. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. Clinical Breast Cancer. 2015;15:e163–6. https://doi.org/10.1016/j.clbc.2014.10.003.
Sibaud V, Niec RE, Schindler K, Busam KJ, Roché H, Modi S, et al. Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. Breast Cancer Research and Treatment. 2014;146:451–6. https://doi.org/10.1007/s10549-014-3001-z.
Corrigan PA, Cicci TA, Auten JJ, Lowe DK. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. The Annals of Pharmacotherapy. 2014;48:1484–93. https://doi.org/10.1177/1060028014545354.
Baron JM, Boster BL, Barnett CM. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Journal of Oncology Pharmacy Practice. 2015;21:132–42. https://doi.org/10.1177/1078155214527144.
Patel KC, Hageman K, Cooper MR. Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. American Journal of Health-System Pharmacy. 2014;71:537–48. https://doi.org/10.2146/ajhp130342.
Dawood S, Sirohi B. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer. Future Oncology (London, England). 2015;11:923–31. https://doi.org/10.2217/fon.15.7.
Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. The New England Journal of Medicine. 2015;372:724–34. https://doi.org/10.1056/NEJMoa1413513.
Kawajiri H, Takashima T, Kashiwagi S, Noda S, Onoda N, Hirakawa K. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Expert Review of Anticancer Therapy. 2015;15:17–26. https://doi.org/10.1586/14737140.2015.992418.
Miller KD, Diéras V, Harbeck N, Andre F, Mahtani RL, Gianni L, et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2014;32:1437–44. https://doi.org/10.1200/JCO.2013.52.6590.
McCormack PL. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer. Drugs. 2013;73:1491–502. https://doi.org/10.1007/s40265-013-0109-0.
Cortés J, Baselga J, Im Y-H, Im S-A, Pivot X, Ross G, et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Annals of oncology: Official Journal of the European Society for Medical Oncology / ESMO. 2013;24:2630–5. https://doi.org/10.1093/annonc/mdt274.
Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, et al. Phase I trial of the trifunctional anti-HER2 × Anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clinical Cancer Research. 2006;12:3085–91. https://doi.org/10.1158/1078-0432.CCR-05-2436.
Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opinion on Investigational Drugs. 2008;17:1553–8. https://doi.org/10.1517/135437126.96.36.1993.
Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Research. 2009;69:4270–6. https://doi.org/10.1158/0008-5472.CAN-08-2861.
Fabi A, Merola R, Ferretti G, Benedetto AD, Antoniani B, Ercolani C, et al. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. Expert Opinion on Pharmacotherapy. 2013;14:699–706. https://doi.org/10.1517/14656566.2013.779672.
Fujita Y, Mizuta N, Sakaguchi K, Nakatsukasa K, Imai A, Umeda Y, et al. A case of effective lapatinib/capecitabine therapy for HER2-positive breast cancer with multiple brain metastases. Gan to Kagaku Ryoho Cancer & Chemotherapy. 2012;39:1699–702.
Dennie TW, Fleming RA, Bowen CJ, Dar MM, Alberti D, Oliver K, et al. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. Clinical Colorectal Cancer. 2011;10:57–62.
Gamucci T, Moscetti L, Mentuccia L, Pizzuti L, Mauri M, Zampa G, et al. Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients. Journal of Cancer Research and Clinical Oncology. 2014;140:221–6.
Oktay E, Yersal Ö, Meydan N, Sağıroğlu M, Uyanık Ö, Barutca S. Nearly complete response of brain metastases from HER2 overexpressing breast cancer with lapatinib and capecitabine after whole brain irradiation. Case reports in Oncological Medicine. 2013;2013
Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, et al. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology. Breast Cancer. 2014;21:677–83.
Shibasaki M, Tanabe A, Toda T, Sakata H, Ijichi M, Kusaka K, et al. A case of effective whole-brain irradiation and lapatinib/capecitabine combination therapy for HER2-positive breast cancer with multiple brain metastases. Gan to Kagaku RyohoCancer & Chemotherapy. 2015;42:755–7.
Shawky H, Tawfik H. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer—a phase II study. Journal of the Egyptian National Cancer Institute. 2014;26:187–94.
Janni W, Sarosiek T, Karaszewska B, Pikiel J, Staroslawska E, Potemski P, et al. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Research and Treatment. 2014;143:493–505.
Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology. 2010;28:1124–30.
Ahmad A, Kong D, Wang Z, Sarkar SH, Banerjee S, Sarkar FH. Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. Journal of Cellular Biochemistry. 2009;108:916–25. https://doi.org/10.1002/jcb.22323.
Huang T-H, Chiu Y-H, Chan Y-L, Chiu Y-H, Wang H, Huang K-C, et al. Prophylactic administration of fucoidan represses cancer metastasis by inhibiting vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in Lewis tumor-bearing mice. Marine Drugs. 2015;13:1882–900. https://doi.org/10.3390/md13041882.
Kim G-E, Lee JS, Choi Y-D, Lee K-H, Lee JH, Nam JH, et al. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer. BMC Cancer. 2014;14:959. https://doi.org/10.1186/1471-2407-14-959.
Magee PJ, Allsopp P, Samaletdin A, Rowland IR. Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2. European Journal of Nutrition. 2014;53:345–50. https://doi.org/10.1007/s00394-013-0520-z.
Roomi MW, Kalinovsky T, Rath M, Niedzwiecki A. Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines. Oncology Reports. 2012;28:768–76. https://doi.org/10.3892/or.2012.1879.
Artacho-Cordón F, Ríos-Arrabal S, Lara PC, Artacho-Cordón A, Calvente I, Núñez MI. Matrix metalloproteinases: potential therapy to prevent the development of second malignancies after breast radiotherapy. Surgical Oncology. 2012;21:e143–51. https://doi.org/10.1016/j.suronc.2012.06.001.
Yang F, Zhang T, Wu H, Yang Y, Liu N, Chen A, et al. Design and optimization of novel hydroxamate-based histone deacetylase inhibitors of Bis-substituted aromatic amides bearing potent activities against tumor growth and metastasis. Journal of Medicinal Chemistry. 2014;57:9357–69. https://doi.org/10.1021/jm5012148.
Zhang T, Chen Y, Li J, Yang F, Wu H, Dai F, et al. Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer. Neoplasia (New York, NY). 2014;16:665–77. https://doi.org/10.1016/j.neo.2014.07.009.
Lin K-T, Wang Y-W, Chen C-T, Ho C-M, Su W-H, Jou Y-S. HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of low toxicity modalities for combination cancer therapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2012;18:4691–701. https://doi.org/10.1158/1078-0432.CCR-12-0633.
Saldana SM, Lee H-H, Lowery FJ, Khotskaya YB, Xia W, Zhang C, et al. Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PloS One. 2013;8:e73406. https://doi.org/10.1371/journal.pone.0073406.
Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM, et al. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Research. 2008;68:9712–22. https://doi.org/10.1158/0008-5472.CAN-08-1952.
Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. British Journal of Cancer. 2006;95:1220–8. https://doi.org/10.1038/sj.bjc.6603354.
Hunter KW, Crawford NP, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 2008;10(Suppl 1):S2. https://doi.org/10.1186/bcr1988.
Minko T, Dharap SS, Pakunlu RI, Wang Y. Molecular targeting of drug delivery systems to cancer. Current Drug Targets. 2004;5(4):389–406.
Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. Journal of controlled Release : Official Journal of the Controlled Release Society. 2016;243:250–68. https://doi.org/10.1016/j.jconrel.2016.10.014.
Minko T. Receptor mediated delivery systems for cancer therapeutic. In: Siegel RA, Juergen S, Rathbone M, editors. Advances in delivery science and technology. CRS Press, Springer; 2012. p. 329–55.
Minko T, Khandare JJ, Vetcher AA, Soldatenkov VA, Garbuzenko OB, Saad M et al. Multifunctional nanotherapeutics for cancer. In: Torchilin VP, editor. Multifunctional pharmaceutical nanocarriers. Springer 2008. p. 309-35.
Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(50) https://doi.org/10.1038/35065016. https://www.nature.com/articles/35065016#supplementary-information.
Cimpean AM, Tamma R, Ruggieri S, Nico B, Toma A, Ribatti D. Mast cells in breast cancer angiogenesis. Crit Rev Oncol Hematol. 2017;115:23–6. https://doi.org/10.1016/j.critrevonc.2017.04.009.
Chellappan DK, Chellian J, Ng ZY, Sim YJ, Theng CW, Ling J, et al. The role of pazopanib on tumour angiogenesis and in the management of cancers: a review. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2017;96:768–81. https://doi.org/10.1016/j.biopha.2017.10.058.
Ye L, Jiang WG. Bone morphogenetic proteins in tumour associated angiogenesis and implication in cancer therapies. Cancer Lett. 2016;380(2):586–97. https://doi.org/10.1016/j.canlet.2015.10.036.
Ribatti D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A. Angiogenesis and antiangiogenesis in triple-negative breast cancer. Translational Oncology. 2016;9(5):453–7. https://doi.org/10.1016/j.tranon.2016.07.002.
Braicu C, Chiorean R, Irimie A, Chira S, Tomuleasa C, Neagoe E, et al. Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy. Expert Reviews in Molecular Medicine. 2016;18:e18. https://doi.org/10.1017/erm.2016.17.
Goyal A, Duley L, Fakis A. Axillary treatment for patients with early breast cancer and lymph node metastasis: systematic review protocol. World J Surg Oncol. 2013;11:6. https://doi.org/10.1186/1477-7819-11-6.
Abreu EB, Martinez P, Betancourt L, Romero G, Godoy A, Bergamo L. Treatment plan for breast cancer with sentinel node metastasis. Ecancermedicalscience. 2014;8:383. https://doi.org/10.3332/ecancer.2014.383.
Erdogan B, Cicin I. Medical treatment of breast cancer bone metastasis: from bisphosphonates to targeted drugs. Asian Pac J Cancer Prev. 2014;15(4):1503–10.
Demirkan B. The roles of epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in breast cancer bone metastasis: potential targets for prevention and treatment. Journal of clinical medicine. 2013;2(4):264–82. https://doi.org/10.3390/jcm2040264.
Arslan C, Dizdar O, Altundag K. Systemic treatment in breast-cancer patients with brain metastasis. Expert Opin Pharmacother. 2010;11(7):1089–100. https://doi.org/10.1517/14656561003702412.
Li Y, Meeran SM, Tollefsbol TO. Combinatorial bioactive botanicals re-sensitize tamoxifen treatment in ER-negative breast cancer via epigenetic reactivation of ERalpha expression. Sci Rep. 2017;7(1):9345. https://doi.org/10.1038/s41598-017-09764-3.
van la Parra RFD, Tadros AB, Checka CM, Rauch GM, Lucci A Jr, Smith BD, et al. Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. The British journal of surgery. 2018;105(5):535–43. https://doi.org/10.1002/bjs.10755.
Carotenuto P, Roma C, Rachiglio AM, Botti G, D'Alessio A, Normanno N. Triple negative breast cancer: from molecular portrait to therapeutic intervention. Critical reviews in eukaryotic gene expression. 2010;20(1):17–34.
Teng YH, Thike AA, Wong NS, Tan PH. Therapeutic targets in triple negative breast cancer—where are we now? Recent patents on anti-cancer drug discovery. 2011;6(2):196–209.